Molecular Mammography of Her-2 Cancers using Gold Nanoparticles

使用金纳米粒子对 Her-2 癌症进行分子乳房 X 线摄影

• 批准号: 7666117
• 负责人: James F Hainfeld
• 金额: $ 48.32万
• 依托单位: NANOPROBES, INC.
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-26 至 2012-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7666117
• 关键词: Accounting; Address; Alpha Particles; Animals; Anodes; Antibodies; Arecaceae; Binding; Biochemical; Biocompatible; Biodistribution; Biopsy; Biopsy Specimen; Blood Vessels; Breast; Breast Cancer Cell; Breast Cancer Early Detection; Caliber; Cells; Characteristics; Clinical; Clinical Trials; Contrast Media; Coupling; Dancing; Detection; Diagnosis; Digital Mammography; Dose; Early Diagnosis; Evaluation; Film; Gold; Gold Colloid; Graph; Hepatic; Human; Image; Image-Guided Surgery; Imaging Phantoms; Immunoconjugates; In Vitro; Injection of therapeutic agent; Investigation; Lesion; Liposomes; Magnetic Resonance Imaging; Malignant Neoplasms; Mammary Neoplasms; Mammography; Measurement; Methods; Molecular; Molecular Sieve Chromatography; Molecular Target; Molybdenum; Monitor; Monoclonal Antibodies; Mus; Mutation Detection; Nanotechnology; Neoplasm Metastasis; Noise; Operative Surgical Procedures; Pain; Patients; Performance; Pharmaceutical Preparations; Phase; Positron-Emission Tomography; Principal Investigator; Proteins; Public Health; Radiation therapy; Radioactive; Radionuclide Imaging; Research; Resolution; Roche brand of trastuzumab; Sampling; Screening procedure; Signal Transduction; Sodium Selenite; Spectrum Analysis; System; Techniques; Technology; Testing; Toxic effect; Tube; absorption; antibody conjugate; attenuation; base; cancer imaging; cancer therapy; cancer type; clinical application; computerized; cost effective; follow-up; gel electrophoresis; image processing; improved; in vivo; insight; irradiation; malignant breast neoplasm; molecular imaging; mouse model; nanoparticle; nanoscale; neoplastic; novel; outcome forecast; particle; performance tests; pre-clinical; programs; prototype; response; sensor; single photon emission computed tomography; synchrotron radiation; tomography; tumor; uptake

DESCRIPTION (provided by applicant): Cancer imaging is important for tumor detection, determination of prognosis and treatments, image guided surgery and irradiation, as well as for monitoring responses. Molecular imaging of specific targets could identify tumor types and enable selection of appropriate drugs. Although x-ray imaging is widely used and more rapid with higher resolution compared to PET, SPECT, and MRI, there are currently no targeted x-ray contrast agents. In this proposal we will develop molecular targeted agents for mammography by a nanotechnology approach using gold nanoparticles for imaging cancers. The Her 2 protein on breast cancer cells will be targeted by use of antibodies attached to biocompatible gold nanoparticles using a mouse model. This would then be useful for non-invasive in vivo detection of this mutation which occurs in about 30% of human breast cancers that could then be beneficially treated with the monoclonal antibody Herceptin(r). Molecular mammography imaging would improve on the limited sampling afforded by painful biopsies and provide more thorough detection of even small tumors and metastases missed by biopsies and other methods. It would enable earlier detection of breast cancer. Better tumor definition would also improve precise radiotherapy, surgery, and follow-up monitoring. If successful, this technology could be applied to other tumors for early detection and biochemical typing for more effective individualized treatments. To Public Health: A novel method using nanotechnology will be developed for improved non-invasive imaging and detection of breast cancer types by mammography. This should not only enable better early detection of smaller tumors and metastases without painful biopsies, but identify tumor types so that specific drugs for the type can be administered. Such a need exists to detect Her2 breast cancers, which account for about 30% of breast cancers, where the specific drug Herceptin(r) is available and improves survival.

描述（由申请人提供）：癌症成像对于肿瘤检测、确定预后和治疗、图像引导手术和放射以及监测反应非常重要。特定靶点的分子成像可以识别肿瘤类型，并选择合适的药物。虽然X射线成像被广泛使用，并且与PET、SPECT和MRI相比具有更高的分辨率，但目前没有靶向X射线造影剂。在这项提案中，我们将开发分子靶向剂的乳腺摄影的纳米技术方法，使用金纳米粒子成像癌症。乳腺癌细胞上的Her 2蛋白将通过使用小鼠模型使用附着于生物相容性金纳米颗粒的抗体来靶向。这将有助于非侵入性体内检测这种突变，这种突变发生在约30%的人类乳腺癌中，然后可以用单克隆抗体赫赛汀（r）进行有益的治疗。分子乳腺X线摄影成像将改善痛苦的活检提供的有限采样，并提供更彻底的检测，即使是小肿瘤和转移错过活检和其他方法。这将有助于早期发现乳腺癌。更好的肿瘤定义也将改善精确的放射治疗，手术和随访监测。如果成功，这项技术可以应用于其他肿瘤的早期检测和生化分型，以获得更有效的个性化治疗。公共卫生：将开发一种使用纳米技术的新方法，用于改进非侵入性成像和通过乳房X光检查检测乳腺癌类型。这不仅可以更好地早期检测较小的肿瘤和转移，而无需进行痛苦的活检，而且可以识别肿瘤类型，以便可以针对该类型给予特定药物。存在检测Her2乳腺癌的这种需求，Her2乳腺癌占乳腺癌的约30%，其中特异性药物Herceptin（r）可用并提高存活率。